BIORESTORATIVE THERAPIES, INC. (OTCMKTS:BRTX) Files An 8-K Regulation FD Disclosure
Item 7.01

Regulation FD Disclosure.

BioRestorative Therapies, Inc. (the "Company") intends to use and discuss, from time to time, on and after May 31, 2018, in presentations about the Company's business, a report prepared by Defined Health with regard to the Company's lead cell therapy candidate, BRTX-100, together with a product profile prepared by Defined Health with regard to BRTX-100 (the "Presentation Materials"). Defined Health was engaged by the Company to review BRTX-100 clinical material and to facilitate discussions with relevant key opinion leaders (KOLs) (i.e., orthopedic surgeons specializing in back and spine surgery, with experience in stem cell therapy) to better understand the future therapeutic potential of BRTX-100. Defined Health is a business development strategy consulting firm with clients in the pharmaceutical, biotech and healthcare industries. The Company may use the Presentation Materials in presentations to current and potential investors, lenders, creditors, insurers, vendors, customers, employees and others with an interest in the Company and its business.

The information contained in the Presentation Materials is summary information that should be considered in the context of the Company's filings with the Securities and Exchange Commission and other public announcements that the Company may make by press release or otherwise from time to time. The Presentation Materials speak as of the date of this Current Report on Form 8-K. While the Company may elect to update the Presentation Materials in the future to reflect events and circumstances occurring or existing after the date of this Current Report on Form 8-K, the Company specifically disclaims any obligation to do so. The Presentation Materials are furnished as Exhibits 99.1 and 99.2 to this Current Report on Form 8-K and are incorporated herein by reference. The presentation materials will also be posted in the Investor Relations section of the Company's website, www.biorestorative.com, for 90 days.

The information referenced under Item 7.01 (including Exhibits 99.1 and 99.2 referenced in Item 9.01 below) of this Current Report on Form 8-K is being "furnished" under "Item 7.01. Regulation FD Disclosure" and, as such, shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The information set forth in this Current Report on Form 8-K (including Exhibits 99.1 and 99.2 referenced in Item 9.01 below) shall not be incorporated by reference into any registration statement, report or other document filed by the Company to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

(d) Exhibits.

99.1Defined Health Report

99.2Defined Health Product Profile

BioRestorative Therapies, Inc. Exhibit
…
To view the full exhibit click here

About BIORESTORATIVE THERAPIES, INC. (OTCMKTS:BRTX)

BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols, involving adult (non-embryonic) stem cells. The Company offers human and plant stem cell derived cosmetic and skin care products. Its programs relate to the treatment of disc/spine disease and metabolic disorders and include Disc/Spine Program (brtxDISC) and Metabolic Program (ThermoStem). Its curved needle device (CND) is a needle system with a curved inner cannula to allow access to difficult-to-locate regions for the delivery or removal of fluids and other substances. The CND is intended to deliver stem cells and/or other therapeutic products or material to the interior of a human intervertebral disc, the spine region, or other areas of the body. The device relies on the use of pre-curved nested cannulae that allows the cells or material to be deposited in the posterior and lateral aspects of the disc to which direct access is not possible due to outlying structures.